Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
Publishing timestamp: 2023-07-07 14:11:51
Summary
The article discusses the approval of the Alzheimer's drug Leqembi by the FDA and its potential impact on sales. While the drug is the first to slow the progression of Alzheimer's in people at early stages, there are logistical requirements and challenges that could initially slow down sales. Medicare has announced coverage for the drug, but with certain conditions. Analysts believe that sales could pick up in 2024, but there are concerns about Medicare requirements, the need for a registry, and testing requirements that could impact the accessibility and prescription of the drug. Overall, analysts expect a slow ramp in 2023 and an acceleration in sales in 2024.
Sentiment: MIXED
Keywords: business, biotech and pharmaceuticals, health care industry, alzheimer's disease, business news, biotechnology, fda, eisai co ltd, social issues, science, biogen inc, pharmaceuticals,
Source: https://www.cnbc.com/2023/07/07/alzheimers-drug-leqembi-sales-may-be-slow-at-first-analysts.html